Kivizidiale

Timolol/Travoprost, the active ingredient in Kivizidiale, is a beta‑blocker; prostaglandin analog presented as an ophthalmic solution for ocular use. It treats primary open‑angle glaucoma and ocular hypertension in adult patients, helping to lower intra‑ocular pressure and reduce risk of vision loss. The dual action provides complementary mechanisms for consistent pressure control.

GNH USA supplies Kivizidiale as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kivizidiale is indicated for conditions that require reduction of intra‑ocular pressure within the glaucoma disease spectrum.

- Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent conversion to glaucoma. - Secondary open‑angle glaucoma: helps control pressure when caused by other ocular conditions.

Kivizidiale may cause ocular and systemic adverse reactions.

Common Side Effects: - Eye irritation or burning sensation. - Blurred vision. - Redness of the eye. - Dry eye or itching. - Foreign body sensation.

Serious or Rare Side Effects: - Severe allergic reaction (angioedema, swelling). - Marked bradycardia or heart block. - Bronchospasm or worsening asthma. - Persistent eye pain or vision loss. - Systemic hypotension.

Before initiating therapy, consider the following precautions.

- Assess cardiovascular status: avoid in patients with severe bradycardia or heart block. - Evaluate respiratory history: caution in asthma or COPD. - Monitor intra‑ocular pressure: ensure adequate pressure reduction. - Avoid concurrent use with other beta‑blocker eye drops: may increase systemic absorption. - Store at room temperature: keep in the original container, protect from light and moisture.

Kivizidiale can interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Systemic beta‑blockers: additive bradycardia or hypotension. - Non‑selective beta‑blocker eye drops: increased systemic exposure. - Monoamine oxidase inhibitors: potential hypertensive crisis (rare).

Moderate Interactions (Monitor Closely): - Carbonic anhydrase inhibitors: additive intra‑ocular pressure lowering. - Topical corticosteroids: may reduce prostaglandin efficacy. - Systemic antihypertensives: monitor blood pressure.